StreetInsider.com News Articles

Form 8-K VERTEX PHARMACEUTICALS For: Oct 20

Tue, 20 Oct 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20261020/27210526.html

Vertex Pharmaceuticals adds ex-Boston Scientific CFO to its board

Tue, 20 Oct 2026 16:05:23 -0400

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) has appointed Daniel Brennan as an independent member of its Board of Directors, expanding the board from 10 to 11 members, according to a company statement.

Brennan brings more than 35 years of finance experience in the healthcare industry, including over 25 years at Boston Scientific Corporation, a medical device and healthcare technology company. He most recently served as Boston Scientific's Executive Vice President and Chief Financial Officer, where he oversaw global finance functions and corporate business development before retiring last year.

Jeffrey Leiden, M.D., Ph.D., Executive Chairman of Vertex, commented on the appointment: "Dan's extensive financial

Vertex Appoints Daniel Brennan to its Board of Directors

Tue, 20 Oct 2026 16:05:00 -0400

BOSTON--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Daniel Brennan has been appointed to its Board of Directors as an independent director. Mr. Brennan has more than 35 years of experience in finance roles at leading healthcare companies, including more than 25 years at Boston Scientific Corporation, a medical device and healthcare technology company. Mr. Brennan retired last year from serving as Boston Scientific’s Executive Vice President, Chief Financial Officer, where he had responsibility for all global finance functions and corporate business development.

“Dan’s extensive financial leadership experience and deep understanding of

Vertex Appoints Daniel Brennan to its Board of Directors

Tue, 20 Oct 2026 16:05:00 -0400

“Dan’s extensive financial leadership experience and deep understanding of

Form 4 VERTEX PHARMACEUTICALS For: Oct 15 Filed by: SACHS BRUCE I

Mon, 19 Oct 2026 16:23:00 -0400

si-local-file:///var/storage/secattach/20261019/27204173.html

Form 4 VERTEX PHARMACEUTICALS For: Oct 15 Filed by: Garber Alan M

Mon, 19 Oct 2026 16:21:00 -0400

si-local-file:///var/storage/secattach/20261019/27204150.html

Vortex Energy Corp. Announces Extension of Marketing Program

Thu, 15 Oct 2026 17:00:00 -0400

VANCOUVER, British Columbia, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Vortex Energy Corp. (CSE: VRTX) (OTC: VTECF) (FSE: AA3) (“Vortex” or the “Company”) is pleased to announce, further to its news release on July 24, 2026, that it has extended its engagement of MCS Market Communication Service GmbH (“MCS”) (address: Rheinpromenade 13, 0789 Monheim am Rhein; email: info@mcsmarket.de) to provide marketing services for an expected term of 45 days, commencing Oct 19, 2026, provided that the term of the marketing services may be extended or shortened at the discretion of management depending on, amongst other things, the

Vortex Energy Corp. Announces Extension of Marketing Program

Thu, 15 Oct 2026 17:00:00 -0400

Vortex Energy Corp. Announces Extension of Marketing Program

Thu, 15 Oct 2026 17:00:00 -0400

Vortex Energy Corp. Announces Extension of Marketing Program

Thu, 15 Oct 2026 17:00:00 -0400

Truist Securitas's Biotechnology Earnings Preview: 'INSM, BBIO, NBIX Most Levered to the Print'

Mon, 12 Oct 2026 09:04:19 -0400

Truist Securitas's Biotechnology Earnings Preview

The analyst commented: "Ahead of 3Q26 earnings prints, we provide our latest thoughts on the set-ups and updated sales estimates for our commercial stage biotech companies: ALNY, ARGX, BBIO, BIIB, HRMY, INSM, NBIX, and VRTX. We continue to view catalysts beyond earnings as the primary drivers of performance across our coverage through year-end. The notable exceptions are INSM, BBIO, and NBIX, where we expect 3Q results to drive the greatest near-term share-price volatility.